50915-97-4

Basic information

• Product Name: Benzoyl chloride, 3,4,5-triethoxy-
• CAS NO: 50915-97-4
• Molecular Formula: C13H17ClO4
• Molecular Weight: 272.729
• Mol File: 50915-97-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzoyl chloride, 3,4,5-triethoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 3,4,5-triethoxy-(50915-97-4)
• EPA Substance Registry System: Benzoyl chloride, 3,4,5-triethoxy-(50915-97-4)

Safety Data

• Hazardous Substances Data: 50915-97-4(Hazardous Substances Data)

Upstream product

• 149-91-7 3,4,5-trihydroxybenzoic acid 
• 6970-19-0 3,4,5-triethoxybenzoic acid 

Downstream Products

• 82763-51-7 3,4,5-Triethoxy-benzoic acid 4-[ethyl-(6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-amino]-butyl ester 
• 1192927-97-1 N-(3-benzamidophenylcarbamothioyl)-3,4,5-triethoxybenzamide 
• 1192928-02-1 N-(3-benzamidophenylcarbamoyl)-3,4,5-triethoxybenzamide 
• 1154010-69-1 C₁₄H₁₇NO₄S 
• 431983-11-8 N-(3-(benzo[d]oxazol-2-yl)-4-chlorophenyl)-3,4,5-triethoxybenzamide 
• 477510-55-7 N-(3-(1H-benzo[d]imidazol-2-yl)phenyl)-3,4,5-triethoxybenzamide 
• 1025867-05-3 N-(4-chloro-3-(1H-indol-2-yl)phenyl)-3,4,5-triethoxybenzamide 
• 1184871-68-8 N-(4-chloro-3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)-3,4,5-triethoxybenzamide 
• 1184871-69-9 N-(4-chloro-3-(1H-imidazol-2-yl)phenyl)-3,4,5-triethoxybenzamide 
• 1348567-79-2 N-(3-(benzo[d]thiazol-2-yl)-4-chlorophenyl)-3,4,5-triethoxybenzamide 
• 167262-84-2 1-(3,4,5-triethoxy-benzoyl)-3-(3,4-dimethoxy-phenyl)-3-(2-hydroxy-ethyl)-pyrrolidine 

Relevant articles and documents

Acylthiourea, acylurea, and acylguanidine derivatives with potent Hedgehog inhibiting activity

The Smoothened (Smo) receptor is the major transducer of the Hedgehog (Hh) signaling pathway. On the basis of the structure of the acylthiourea Smo antagonist (MRT-10), a number of different series of analogous compounds were prepared by ligand-based structural optimization. The acylthioureas, originally identified as actives, were converted into the corresponding acylureas or acylguanidines. In each series, similar structural trends delivered potent compounds with IC50 values in the nanomolar range with respect to the inhibition of the Hh signaling pathway in various cell-based assays and of BODIPY-cyclopamine binding to human Smo. The similarity of their biological activities, in spite of discrete structural differences, may reveal the existence of hydrogen-bonding interactions between the ligands and the receptor pocket. Biological potency of compounds 61, 72, and 86 (MRT-83) were comparable to those of the clinical candidate GDC-0449. These findings suggest that these original molecules will help delineate Smo and Hh functions and can be developed as potential anticancer agents.

3,4,5-Triethoxybenzoic acid derivatives

-